Aldeyra Therapeutics, Inc. (ALDX) EPS Estimated At $-0.32

March 20, 2018 - By reb123z

 Aldeyra Therapeutics, Inc. (ALDX) EPS Estimated At $ 0.32
Investors sentiment increased to 3.13 in 2017 Q3. Its up 1.46, from 1.67 in 2017Q2. It increased, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported.
Adage Cap Prns Group Ltd Liability, a Massachusetts-based fund reported 750,000 shares. 683 Cap Mngmt Llc owns 835,514 shares for 0.63% of their portfolio. Blackrock accumulated 37,667 shares. Bank Of America Corporation De, North Carolina-based fund reported 7,500 shares. Woodstock invested in 48,393 shares. Moreover, Morgan Stanley has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Hightower Advsrs Limited Co has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 29,650 shares. Bank Of Ny Mellon Corporation has invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Ellington Mngmt Ltd Liability Co owns 23,300 shares. Tower Rech Capital (Trc) accumulated 3,183 shares. Fmr holds 1.61 million shares. Prelude Capital Management Lc holds 0% or 1,364 shares in its portfolio. Millennium Ltd owns 545,085 shares or 0.01% of their US portfolio. Sphera Funds Management Ltd invested in 1.07% or 1.04 million shares. Vanguard Gru has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.32 EPS on March, 29.They anticipate $0.04 EPS change or 11.11 % from last quarter’s $-0.36 EPS. After having $-0.32 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 0.59% or $0.05 during the last trading session, reaching $8.4. About 4,533 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has declined 18.94% since March 20, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 9. Cantor Fitzgerald maintained the shares of ALDX in report on Thursday, November 9 with “Buy” rating. The firm earned “Buy” rating on Monday, September 26 by H.C. Wainwright. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Tuesday, October 24 by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, June 15 by H.C. Wainwright. The rating was maintained by Cowen & Co on Thursday, September 14 with “Buy”. The firm has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. The company was maintained on Wednesday, September 13 by Canaccord Genuity. The stock has “Buy” rating by Canaccord Genuity on Wednesday, June 14. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Friday, July 1 by Stifel Nicolaus.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $160.59 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.